There is therapeutic potential in targeting interactions between Gal1 and glycan to overcome immunosuppression in cancer and strengthen antitumoural immunity, as well as treatments aimed to stimulate immunoregulatory processes driven by Gal1 to lessen inflammation. This evidence concerns the gene LGALS1 and cancer.